Expert Insights on HER2+ EBC
Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool

Released: March 19, 2019

Expiration: March 17, 2020

Frankie Ann Holmes
Frankie Ann Holmes, MD, FACP
Sara Hurvitz
Sara Hurvitz, MD
Joyce O’Shaughnessy
Joyce O’Shaughnessy, MD
Mark D. Pegram
Mark D. Pegram, MD
Denise A. Yardley
Denise A. Yardley, MD

Introduction

Did you recently receive a diagnosis of HER2-positive early breast cancer? Use this Interactive Decision Support Tool to view treatment plans before or after surgery from 5 breast cancer experts by answering a series of multiple choice questions about your cancer.

Interactive Decision Support Tool

Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

The “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool is designed to educate patients on optimal regimens for HER2+ early breast cancer, based on specific patient and disease characteristics. The information provided is based on the expert guidance of breast cancer experts Frankie Ann Holmes, MD, FACP; Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; Mark D. Pegram, MD; and Denise A. Yardley, MD.

Although the information contained in the “Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. Patients should always discuss their healthcare decisions with their oncology care team. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Program Content